Oncotarget

Research Papers:

Prognostic value of microRNAs in osteosarcoma: a meta-analysis

Yun Hak Kim, Tae Sik Goh, Chi-Seung Lee, Sae Ock Oh, Jeung Il Kim, Seung Hyeon Jeung and Kyoungjune Pak _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:8726-8737. https://doi.org/10.18632/oncotarget.14429

Metrics: PDF 2288 views  |   HTML 2414 views  |   ?  


Abstract

Yun Hak Kim1,2,*, Tae Sik Goh1,3,*, Chi-Seung Lee4, Sae Ock Oh2, Jeung Il Kim3, Seung Hyeon Jeung3, Kyoungjune Pak1,5

1BEER, Busan Society of Evidence-Based Medicine and Research, Busan, Republic of Korea

2Department of Anatomy, School of Medicine, Pusan National University, Yangsan, Gyeongnam, Republic of Korea

3Department of Orthopaedic Surgery and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea

4Biomedical Research Institute, Pusan National University Hospital and School of Medicine, Pusan National University, Busan, Republic of Korea

5Department of Nuclear Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea

*These authors have contributed equally in this work

Correspondence to:

Kyoungjune Pak, email: [email protected]

Keywords: microRNA, osteosarcoma, prognosis, meta-analysis

Received: November 01, 2016    Accepted: December 01, 2016    Published: January 02, 2017

ABSTRACT

BACKGROUND: Osteosarcoma is the most common primary bone malignancy. We meta-analyzed the prognostic value of altered miRNAs in patients with osteosarcoma.

METHODS: Sources from MEDLINE (from inception to August 2016) and EMBASE (from inception to August 2016) were searched. Studies of osteosarcoma with results of miRNA and studies that reported survival data were included and two authors performed the data extraction independently. Any discrepancies were resolved by a consensus. The outcome was overall survival and event-free survival assessed using hazard ratios (HRs).

RESULTS: After reviewing the full text of 65 articles, 25 studies including 2,278 patients were eligible in this study. The pooled HR for deaths was 1.40 (95% confidence interval [CI] 1.01-1.94, p=0.04) with random-effects model (χ2=113.08, p<0.00001, I2=79%) for patients of osteosarcoma with lower expression of miRNA. However, the pooled HR for events was not significant (HR 0.97, 0.63-1.48, p=0.87, χ2=72.65, p<0.00001, I2=79%). In pathway analysis of miRNAs, miRNA449a, 199-5p, 542-5p have common target genes.

CONCLUSIONS: Expression level of miRNA in patients of osteosarcoma is important as a prognostic factor.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14429